Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer

Yilmaz H., YILMAZ A., Demirag G.

FUTURE ONCOLOGY, cilt.17, ss.3853-3864, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2217/fon-2021-0040
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.3853-3864
  • Anahtar Kelimeler: hemoglobin, lymphocyte, monocyte, prognosis, red cell distribution width, renal cell carcinoma, survival, PREOPERATIVE ANEMIA, LYMPHOCYTE RATIO, LATE RECURRENCE, LUNG-CANCER, CARCINOMA, INFLAMMATION, SURVIVAL, NEPHRECTOMY, NEUTROPHIL, MANAGEMENT
  • Atatürk Üniversitesi Adresli: Evet

Özet

The aim of the current research was to investigate the prognostic significance of pretreatment hemoglobin-to-red cell distribution width ratio (HRR) in patients with renal cell carcinoma (RCC). The neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio (LMR) and HRR were analyzed retrospectively to assess their prognostic value using Kaplan-Meier curves and Cox regression analysis in 198 patients with RCC. High HRR (0.72) and high LMR (2.43) were found to be associated with longer progression-free survival and overall survival. A multivariate analysis identified International Metastatic Renal Cell Carcinoma Database Consortium prognostic score, tumor stage, node stage, LMR and HRR as independent prognostic factors for progression-free survival, as well as International Metastatic Renal Cell Carcinoma Database Consortium score, neutrophil-to-lymphocyte ratio and HRR for overall survival. HRR is a an independent prognostic parameter predicting the progression and survival of patients with RCC.